Ollin
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Austin, Texas, United StatesWebsite
ollin.bioRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Ollin
Ollin Biosciences is a clinical-stage biopharmaceutical company focused on developing best-in-disease therapies for vision-threatening ophthalmology conditions. Founded in 2023, the company is building a differentiated pipeline targeting areas such as wet age-related macular degeneration and diabetic macular edema. Ollin is advancing programs for autoimmune and inflammatory eye diseases. Headquartered in Austin, Texas, the company aims to accelerate innovation in ophthalmology through strong scientific and clinical execution.Explore more
Ollin Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ollin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ollin is spiking on competitors!
Ollin, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ollin has recently received funding, and reach out quickly before it becomes old news!
Click to see if Ollin had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Ollin has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Ollin recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Ollin
Product Launch: Get notified when Ollin launches new products
Recommended Actions
Find VP level buyers at Ollin
Find 2 more new buyers
Company Profile Activity
Activity Insights
Ollin is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ollin is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ollin.
Ollin financials insights
Gather financial insights about Ollin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Unspecified
$100M
2026
Series B
$330M
Ollin Tech Stack
A closer look at the technologies used by Ollin
Ollin News & Media
Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3 - BioSpace
With positive feedback on a Phase 3 trial design, Ollin Biosciences has collected a $330 million series B to advance its VEGF/Ang2 antibody, which bested Genentech’s therapy in a head-to-head study.Ollin Biosciences, an ophthalmology venture, grabs investors' attention - STAT News
The company, which is developing treatments for eye diseases, has raised $330 million from investors as it readies for late-stage testing.Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable...Innovent's Partner Ollin Biosciences Announces Final Data from Randomized Head-to-Head Study of IBI324 Compared to Faricimab (Vabysmo) in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics advancing OLN324 into global Phase 3 studies in DME and wAMD in 2026 SAN FRANCISCO and SUZHOU, China,
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ollin
Sign Up For FreeTo access detailed company insights
Ollin Biosciences is a clinical-stage biopharmaceutical company focused on developing best-in-disease therapies for vision-threatening ophthalmology conditions. Founded in 2023, the company is building a differentiated pipeline targeting areas such as wet age-related macular degeneration and diabetic macular edema. Ollin is advancing programs for a... Read More
